Organization
Freie Universität Berlin
4 abstracts
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Rapid establishment of patient-derived organoids from treatment-naive head and neck cancer patients for drug and radiosensitivity screening.Org: Charité University Hospital, Charite University Hospital Berlin, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin,